Emerald BioStructures and UCB Announce Multi-year Extension

The strategic aspects of this renewed relationship will provide Emerald with research funding over the three-year period and the opportunity to receive milestones and royalties on future drug product revenues.

“The collaborative nature of our relationship with the team at Emerald BioStructures has been instrumental in elucidating multiple targets and identifying promising, novel lead compounds in our discovery programs,” commented Dr. Ismail Kola, President, UCB NewMedicines.

Emerald will apply its high-throughput crystallography and ligand characterization expertise to provide fragment screening and structural biology support for UCB’s severe diseases discovery programs. Emerald and UCB first entered into collaboration in February 2009.

“It is our mission to enable companies like UCB with structural insights,” commented Diana Wetmore, VP of Business Development and Alliances at Emerald BioStructures. “We are very excited about moving into this new phase with UCB, expanding our role in the discovery of breakthrough medicines for unmet needs.”